Compare Abbott Laboratories (ABT) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while Vanguard Dividend Appreciation Index Fund ETF trades at $237.71. The key difference: Abbott Laboratories pays a 2.63% dividend while Vanguard Dividend Appreciation Index Fund ETF pays none, and Vanguard Dividend Appreciation Index Fund ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | VIG | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | — |
52-Week High | $136.62 | $239.03 |
52-Week Low | $82.57 | $204.09 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
VIG trades at $238.88, up 0.11% with a bullish technical outlook supported by moving averages. The ETF focuses on U.S. companies with consistent dividend growth, maintaining a low 0.04% expense ratio. Recent news highlights its role in long-term wealth building through dividend compounding, though some analysts favor competitors like DGRO for momentum.
The outlook remains positive for income-focused investors seeking steady dividend growth, but risks include sector concentration in technology and competition from higher-yield alternatives. Wall Street sentiment is generally favorable, with the ETF's strategy appealing for passive income portfolios amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
